HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways.
HIV-infected individuals taking antiretroviral medications may experience changes in body shape and metabolism, commonly known as HIV-associated lipodystrophy (HIVLD). In vitro and in vivo research have revealed numerous effects of both protease inhibitors and nucleoside reverse transcriptase inhibitors on the function of various organs--most importantly adipose tissue, liver, and muscle. The metabolic abnormalities could result in an increased risk of cardiovascular disease in this vulnerable and relatively young population. Treatment strategies, normally successful in the general population, have generally been less effective in this group of people, in which the detrimental effects of the antiretroviral medications are ongoing.
Mallon
Patrick W G
PW
National Centre in HIV Epidemiology and Clinical Research, St. Vincent's Hospital Medical Centre, 376 Victoria Street, Sydney NSW 2010, Australia. pmallon@nchecr.unsw.edu.au
Carr
Andrew
A
Cooper
David A
DA
D017667:Adipocytes / Q000378:metabolism / Q000473:pathology; D039682:HIV-Associated Lipodystrophy Syndrome / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D006801:Humans; D006949:Hyperlipidemias / Q000378:metabolism / Q000473:pathology / Q000821:virology; D007333:Insulin Resistance